Rovin Capital UT ADV Buys 3,660 Shares of Geron Co. (NASDAQ:GERN)

Rovin Capital UT ADV boosted its stake in shares of Geron Co. (NASDAQ:GERN) by 26.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,270 shares of the biopharmaceutical company’s stock after acquiring an additional 3,660 shares during the period. Rovin Capital UT ADV’s holdings in Geron were worth $61,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GERN. RTW Investments LP bought a new stake in shares of Geron during the 3rd quarter worth approximately $200,268,000. State Street Corp lifted its stake in Geron by 28.4% during the third quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock worth $131,486,000 after purchasing an additional 6,413,204 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in Geron during the second quarter worth $106,185,000. Janus Henderson Group PLC boosted its holdings in shares of Geron by 140.0% in the 3rd quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock valued at $102,193,000 after purchasing an additional 13,163,889 shares in the last quarter. Finally, Holocene Advisors LP bought a new position in shares of Geron in the 3rd quarter valued at $82,498,000. 73.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on GERN shares. Barclays raised shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. Scotiabank began coverage on Geron in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Geron in a report on Tuesday, December 10th. Finally, Needham & Company LLC lifted their price target on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $7.25.

Geron Stock Performance

NASDAQ:GERN opened at $2.92 on Friday. The company has a market capitalization of $1.77 billion, a PE ratio of -9.13 and a beta of 0.55. Geron Co. has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The company has a 50 day simple moving average of $3.70 and a two-hundred day simple moving average of $4.19.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. The business had revenue of $28.27 million during the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. Geron’s quarterly revenue was up 17138.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.08) earnings per share. Research analysts anticipate that Geron Co. will post -0.25 earnings per share for the current year.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.